Status:
TERMINATED
Colchicine in Patients With Mild and Severe Coronavirus Disease
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions:
COVID
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The world is currently facing a pandemic due to the outbreak of a new coronavirus causing acute respiratory failure called SARS-Cov2. The majority of patients (8 out of 10) are known to have mild dise...
Detailed Description
This a placebo-controlled double-blind clinical trial to test the efficacy and security of colchicine 1.5 mg at day one followed by 0.5 mg BID to complete 10 days of treatment. The researchers will re...
Eligibility Criteria
Inclusion
- Patients over 18 years of age
- Diagnosed with COVID-19 with mild or severe disease
- Who must receive in-hospital care at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Who are able to take pills PO
Exclusion
- 1\. Concomitant participation in another clinical trial. 2. Hypersensitivity to colchicine 3. Pregnancy and lactation 4. Over 70 years 5. Kidney failure with creatinine clearance \<30 mL / min. 6. Known liver failure 7. Concomitant medication that has interactions with colchicine and that due to its indication cannot be suspended or substituted
Key Trial Info
Start Date :
May 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2021
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04367168
Start Date
May 27 2020
End Date
August 16 2021
Last Update
August 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Medicas y Nutricion
Mexico City, Mexico, 14080